Importantly, pharmacological inhibit both FGFR and PI3K/AKT signaling significantly reversed GLT8D2-induced chemoresistance and enhanced platinum’s therapeutic efficacy in ovarian cancer, suggesting that GLT8D2 could contribute to FGFR/PI3K/AKT activation and thereby represent a novel target for ovarian cancer treatment. This evidence concerns the gene GLT8D2 and ovarian carcinoma.